Key facts
- This page summarizes Craig B. Granowitz's Form 4 filing for LEXICON PHARMACEUTICALS, INC. (LXRX).
- 7 reported transactions and 3 derivative rows are listed below.
- Accepted by SEC: 03 Mar 2026, 07:19.
Craig B. Granowitz - 28 Feb 2026 Form 4 Insider Report for LEXICON PHARMACEUTICALS, INC. (LXRX)
- Reporting relationship
- SVP, Chief Medical Officer
- Issuer ticker
- LXRX
- Reported as of
- 28 Feb 2026
- Net transaction value
- -$160,374
- SEC form
- 4
- Accepted by SEC
- 03 Mar 2026, 07:19:33 UTC
- Prior SEC filing
- 17 Feb 2026
- Source filing
- View source filing
- Reporting owner signature
- /s/ Craig B. Granowitz, M.D., Ph.D.
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Craig B. Granowitz filed Form 4 for LEXICON PHARMACEUTICALS, INC. (LXRX) on 03 Mar 2026.
Change
- Previous filing in this sequence was filed on 17 Feb 2026.
- Current net transaction value: -$160,374.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reporting Owners (1)
CIK 0001876655
Primary reporting owner
Granowitz Craig B
- Relationship
- SVP, Chief Medical Officer
- Address
- 2445 TECHNOLOGY FOREST BLVD., 11TH FLOOR, THE WOODLANDS
- Signature
- /s/ Craig B. Granowitz, M.D., Ph.D.
- Signature date
- 03 Mar 2026
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
LXRX
transaction
Common Stock
Options Exercise
- Transaction value
- Shares
- +35,790
- Change %
- +30%
- Price
- Shares after
- 156,042
- Date
- 28 Feb 2026
- Ownership
- Direct
- Footnotes
- F1
LXRX
transaction
Common Stock
Options Exercise
- Transaction value
- Shares
- +74,226
- Change %
- +48%
- Price
- Shares after
- 230,268
- Date
- 28 Feb 2026
- Ownership
- Direct
- Footnotes
- F1
LXRX
transaction
Common Stock
Options Exercise
- Transaction value
- Shares
- +202,260
- Change %
- +88%
- Price
- Shares after
- 432,528
- Date
- 28 Feb 2026
- Ownership
- Direct
- Footnotes
- F1
LXRX
transaction
Common Stock
Tax liability
- Transaction value
- $160,374
- Shares
- -109,098
- Change %
- -25%
- Price
- $1.47
- Shares after
- 323,430
- Date
- 28 Feb 2026
- Ownership
- Direct
- Footnotes
- F2
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
LXRX
transaction
Derivative
Restricted Stock Units
Options Exercise
- Transaction value
- Shares
- -35,790
- Change %
- -100%
- Price
- Shares after
- 0
- Date
- 28 Feb 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 35,790
- Exercise price
- Footnotes
- F1, F3
LXRX
transaction
Derivative
Restricted Stock Units
Options Exercise
- Transaction value
- Shares
- -74,226
- Change %
- -50%
- Price
- Shares after
- 74,227
- Date
- 28 Feb 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 74,226
- Exercise price
- Footnotes
- F1, F3
LXRX
transaction
Derivative
Restricted Stock Units
Options Exercise
- Transaction value
- Shares
- -202,260
- Change %
- -33%
- Price
- Shares after
- 404,520
- Date
- 28 Feb 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 202,260
- Exercise price
- Footnotes
- F1, F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 3 footnotes
Footnote F1
Each restricted stock unit represents a contingent right to receive one share of common stock.
Footnote F2
Withholding of a portion of issued shares by the Company in satisfaction of shareholder's tax withholding obligations with respect thereto.
Footnote F3
Restricted stock units vest with respect to 1/3 of the shares subject to the restricted stock units on February 28 of each of the three years following the year of grant.